Xolremdi (mavorixafor) is a CXCR4 antagonist. It's the first medication FDA-approved to treat WHIM syndrome (warts, hypogammaglobulinemia, infections, and myelokathexis), a rare genetic condition that affects the immune system. It can be taken by people ages 12 years and older. Typically, you take Xolremdi (mavorixafor) by mouth once daily in the morning on an empty stomach, after fasting through the night. Some of the most common side effects include rash, vomiting, and nosebleeds.
Xolremdi (mavorixafor) is a CXCR4 antagonist, meaning it blocks the activity of CXCR4 proteins. In a healthy immune system, these proteins tell white blood cells (WBCs) to stay in the bone marrow where they can grow and mature. When there’s an infection, CXCR4 proteins tell the WBCs to move into the bloodstream where they can fight off the infection.
People who have WHIM syndrome have a change in the CXCR4 gene that makes the CXCR4 proteins overly active. As a result, the WBCs stay trapped in the bone marrow and aren’t able to move into the bloodstream. Xolremdi (mavorixafor) treats WHIM by blocking the CXCR4 proteins so that the WBCs can leave the bone marrow to fight infections in the body.
The following side effects may get better over time as your body gets used to the medication. Let your healthcare provider know immediately if you continue to experience these symptoms or if they worsen over time.
Contact your healthcare provider immediately if you experience any of the following.
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome is a rare genetic condition. People with WHIM have an immune system that doesn't work properly. They have white blood cells (WBCs) that get stuck in the bone marrow (myelokathexis) and lower levels of antibodies in the blood (hypogammaglobulinemia). As a result, they are more prone to infections, including warts caused by viruses. Xolremdi (mavorixafor) treats WHIM by helping WBCs move from the bone marrow into the bloodstream where they can fight infections.
No, Xolremdi (mavorixafor) doesn’t cure WHIM because it doesn’t fix the CXCR4 gene. But rather, it blocks the overactive CXCR4 protein so that the immune cells can move into the bloodstream to defend against germs like bacteria or viruses. As a result, people who take Xolremdi (mavorixafor) might be better able to fight infections. Xolremdi (mavorixafor) is the first medication that's FDA-approved specifically to treat WHIM by targeting CXCR4. Prior treatment options involved managing or preventing specific symptoms of WHIM syndrome, such as raising the number of antibodies with immunoglobulin replacement therapy.
A year-long study looked at how well Xolremdi (mavorixafor) works by measuring how long white blood cell (WBC) counts stayed above levels that reduce the risk of infections. Results showed that people who took Xolremdi (mavorixafor) had WBC counts above this level for much longer compared to those who took placebo. People who took Xolremdi (mavorixafor) also had fewer infections and infections that were less severe compared to those who took placebo. Data suggest that Xolremdi (mavorixafor) isn’t likely to improve warts, but more research is needed in this area. Talk with your healthcare team if you have more questions about how well this medication works.
Yes, Xolremdi (mavorixafor) can interact with certain supplements. For example, taking St. John’s Wort can lower the level of Xolremdi (mavorixafor) in your body and cause it to not work as well. Additionally, taking goldenseal can raise the level of Xolremdi (mavorixafor) and put you at higher risk for side effects like nosebleeds. Tell your healthcare team what vitamins and supplements you are taking so they can help you check for interactions.
No, you shouldn’t take Xolremdi (mavorixafor) if you’re pregnant. Taking this medication during pregnancy might cause harm to your unborn baby. Before starting, your healthcare team will ask you to take a pregnancy test to double check your pregnancy status. If you're able to become pregnant, they’ll recommend effective birth control when taking Xolremdi (mavorixafor) and for 3 weeks after your last dose.
You should avoid breastfeeding while taking Xolremdi (mavorixafor). There’s not enough research to know how this medication might affect breastfed babies. But because there’s a risk of potentially serious side effects, you shouldn’t breastfeed during treatment and for 3 weeks after finishing your last dose.
Xolremdi (mavorixafor) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Due to the way Xolremdi (mavorixafor) works, it might cause harm to unborn babies if taken by mothers during pregnancy. To be safe, people who are pregnant shouldn’t take this medication. If you’re able to become pregnant, your healthcare team will ask you to take a pregnancy test before starting treatment to see if you’re pregnant. Additionally, it’s important that you use an effective form of birth control while taking Xolremdi (mavorixafor) and for 3 weeks after your last dose.
Xolremdi (mavorixafor) can cause a serious heart rhythm problem called long QT syndrome. Before starting this medication, your healthcare team will order an electrocardiogram (ECG) to monitor your heart rate and rhythm. Monitoring is important because people with this condition often don’t notice any symptoms. If you're taking other medications that can cause this side effect, your care team might order ECGs more often during treatment. If needed, your care team will lower your dose of Xolremdi (mavorixafor) to prevent heart rhythm problems. Get medical help right away if you notice symptoms of heart rhythm problems, such as pounding heart, tiredness, dizziness, and fainting.
| Dosage | Quantity | Price as low as | Price per unit |
|---|---|---|---|
| 100mg of | 120 capsules | $44,011.50 | $366.76 |
Your healthcare team will determine your dose of Xolremdi (mavorixafor) based on your weight.
In general:
People who weigh more than 50 kg: The typical dose is 400 mg by mouth in the morning once daily on an empty stomach, after fasting through the night.
People who weigh 50 kg or less: The typical dose 300 mg by mouth in the morning once daily on an empty stomach, after fasting through the night.
Your dose might be different if you're taking another medication that can interact with Xolremdi (mavorixafor).
Contraindications are specific health conditions or situations in which a person should not take a medication due to safety concerns. If you have any of the following conditions or if any of the following apply to you, let your healthcare provider know because Xolremdi (mavorixafor) will not be safe for you to take.